Why Ozempic (Semaglutide 0.5 to 2 mg) Causes Gallbladder Disease: The Mechanism Explained

At a glance

• Label warning / Acute gallbladder disease; if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]
• Label rates / Cholelithiasis 1.5% on 0.5 mg and 0.4% on 1 mg vs none on placebo; cholecystitis is a postmarketing report with no estimable frequency [1]
• Maintenance doses / 0.5, 1 or 2 mg once weekly, increased only after at least 4 weeks at the current dose [1]
• Review conclusion / Semaglutide increases the risk of biliary disease (cholelithiasis) [2]
• Trial context at 2.4 mg / SELECT: gallbladder-related disorders 2.8% vs 2.3%; cholelithiasis 1.4% vs 1.1%; cholecystitis 0.6% vs 0.6% [3]
• Pharmacology / Semaglutide delays gastric emptying [1]

What does the Ozempic label say?

The label lists acute gallbladder disease under warnings and says gallbladder studies are indicated if cholelithiasis or cholecystitis are suspected [1]. In placebo-controlled trials, gallstones were reported in 1.5% of patients taking Ozempic 0.5 mg and 0.4% taking 1 mg, compared with none taking placebo [1]. Cholecystitis and cholecystectomy appear in the label's postmarketing reports, for which frequency cannot be estimated [1]. Ozempic's maintenance doses are 0.5, 1 or 2 mg once weekly, with at least 4 weeks at each step before increasing [1].

Is there evidence that semaglutide raises gallbladder risk?

A review of semaglutide safety concluded that it increases the risk of biliary disease (cholelithiasis) [2]. In a meta-analysis of once-weekly semaglutide in adults with overweight or obesity and no diabetes, gallbladder disorders had an odds ratio of 1.26 and cholelithiasis an odds ratio of 2.06 versus placebo [4]. Those trials were not Ozempic 0.5 to 2 mg trials in type 2 diabetes. In SELECT, which used semaglutide 2.4 mg weekly in adults with established cardiovascular disease and overweight or obesity, gallbladder-related disorders occurred in 2.8% vs 2.3%; cholelithiasis 1.4% vs 1.1%; cholecystitis 0.6% vs 0.6% [3]. The absolute difference was 0.5 percentage points, at a different dose and in a different population from Ozempic's labeled range.

What mechanism is supported?

Ozempic's label reports gallbladder events but does not explain how they occur. It says semaglutide delays gastric emptying [1], but does not link that effect to gallstones.

Is the risk higher at 2 mg than at 0.5 mg?

The label gives gallstone rates for the 0.5 mg and 1 mg groups and none for 2 mg, and the 1 mg rate was lower than the 0.5 mg rate [1]. For 2 mg it reports a 40-week trial of 959 treated patients on 1 mg or 2 mg and says no new safety signals were identified [1]. A dose-dependent increase is not shown by the label's figures.

Frequently asked questions

›Does Ozempic cause gallstones?

The Ozempic label warns of acute gallbladder disease, including cholelithiasis and cholecystitis, and says gallbladder studies are indicated if either is suspected [1]. In placebo-controlled trials, gallstones were reported in 1.5% of patients taking 0.5 mg and 0.4% taking 1 mg, versus none taking placebo [1].

›Is gallbladder risk higher at 2 mg than at 0.5 mg?

The label gives gallstone rates for 0.5 mg and 1 mg only, and no gallbladder rate for 2 mg [1].

›What does the label say to do if gallbladder disease is suspected?

It says gallbladder studies are indicated if cholelithiasis or cholecystitis are suspected [1].

›Is this risk specific to Ozempic?

The warning is on the Ozempic label [1]. Semaglutide is the active drug, and a review concluded semaglutide increases biliary disease risk [2]. In SELECT, semaglutide 2.4 mg showed a small absolute increase in gallbladder-related disorders [3].

References

1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
2. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. Safety of Semaglutide
3. Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33(3):452-462. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
4. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials